间充质干细胞治疗脓毒症的研究进展  

Research progress of mesenchymal stem cell therapy for sepsis

作　　者：邓捷 黄启林[3] 黄尚卿 陈重 李薇 史惠卿 孙红玉 DENG Jie;HUANG Qi-Lin;HUANG Shang-Qing;CHEN Zhong;LI Wei;SHI Hui-Qing;SUN Hong-Yu(Department of Clinical Pharmacy,The General Hospital of Western Theater Command of PLA,Chengdu 610083,China;School of Medicine,Southwest Jiaotong University,Chengdu 610031,China;Tianjin Medical University,Tianjing 300070,China;Department of General Surgery,The General Hospital of Western Theater Command of PLA,Chengdu 610083,China;Department of Ultrasound,The General Hospital of Western Theater Command of PLA,Chengdu 610083,China;Laboratory of Basic Medicine,The General Hospital of Western Theater Command of PLA,Chengdu 610083,China)

机构地区：[1]西部战区总医院临床药学科,成都610083 [2]西南交通大学医学院,成都610031 [3]天津医科大学,天津300070 [4]西部战区总医院普通外科,成都610083 [5]西部战区总医院超声科,成都610083 [6]西部战区总医院基础医学实验室,成都610083

出　　处：《生命科学》2022年第4期420-426,共7页Chinese Bulletin of Life Sciences

基　　金：国家自然科学基金项目(81772001);四川省科技计划项目(2020YFS0122)。

摘　　要：脓毒症是一种严重的、威胁生命的炎症反应综合征,目前仍以对症支持治疗为主。因此,亟需寻找一种新的治疗策略以改善脓毒症患者预后。间充质干细胞(mesenchymal stem cells, MSCs)因其独特的生物学特性,备受生命科学及医学领域研究者青睐。近年来,多项研究表明MSCs可通过调节免疫状态、平衡炎症反应、降低细菌负荷、改善器官功能等途径,进而提高脓毒症机体的生存率,这表明MSCs有望成为脓毒症治疗新策略。本文就MSCs在脓毒症临床前与临床研究中的最新进展作一综述。Sepsis is a serious and life-threatening inflammatory response syndrome, which is still treated mainly by symptomatic support. Therefore, there is an urgent need to find a new treatment strategy to improve the prognosis of patients with sepsis. Mesenchymal stem cells(MSCs) are favored by researchers in the field of life science and medicine because of their unique biological characteristics. In recent years, many studies have shown that MSCs can improve the survival rate of sepsis by regulating immune state, balancing inflammatory response, reducing bacterial load and improving organ function, which indicates that MSCs is expected to be a new strategy for the treatment of sepsis. This article reviews the latest progress of MSCs in preclinical and clinical study of sepsis.

关 键 词：脓毒症 间充质干细胞 临床前研究 临床研究 

分 类 号：R392.5[医药卫生—免疫学] R963[医药卫生—基础医学]